Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New nasal device could make COPD breathing treatments easier

NCT ID NCT02812979

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving the breathing drug salbutamol through a high-flow nasal device works as well as the usual mask method for people with COPD. 25 adults with COPD took part. The goal was to see if the new method is not worse at improving lung function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
salbutamol
What this could lead to
If it works, this could offer a more comfortable way to deliver breathing medication for COPD patients.
What could go wrong
This is a small, early study with only 25 participants, so results may not apply to everyone. It only tests if the new method is not worse than the usual one, not if it is better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Start date

Jun 2016

Finished

Apr 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adults * Patient with chronic obstructive pulmonary disease * Patients, when performing lung function tests performed outside of the study : 1. A report FEV / FVC less than 60% prior to bronchodilator treatment AND 2. A positive reversal test defined by FEV variation of over 12 % and 200 mL after administration of inhaled salbutamol * Patients affiliated to social security scheme * Informed consent signed by the patient Exclusion Criteria: * Exacerbation of chronic obstructive pulmonary disease during * Uncontrolled asthma * Pneumothorax current or recent ( \< 2 months) * Pleural aspiration or biopsy , trans - bronchial biopsies and / or bronchoalveolar lavage in the preceding 48h * hemoptysis in progress * Patient under guardianship or trusteeship safeguard justice * Pregnant or breastfeeding women or parturient woman * Known allergy or intolerance to salbutamol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Service de Réanimation Polyvalente

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.